Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib - Wikidata - wikimedia - TriplyDB

Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib

Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib

http://www.wikidata.org/entity/Q34269139

about

Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients.The utilization of next-generation sequencing to detect somatic mutations and predict clinical prognosis of Chinese non-small cell lung cancer patients.

P2860

Q49450097-00EB4964-2424-4264-8E2B-D6907CD7881A Q55314072-796C4EEA-0F4E-458D-BFD0-0A965777B4DE

P2860

Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib

http://www.wikidata.org/entity/Q34269139

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Getting out of a wheelchair: a ...... f EGFR responsive to erlotinib

@ast

Getting out of a wheelchair: a ...... f EGFR responsive to erlotinib

@en

Getting out of a wheelchair: a ...... f EGFR responsive to erlotinib

@nl

type

label

Getting out of a wheelchair: a ...... f EGFR responsive to erlotinib

@ast

Getting out of a wheelchair: a ...... f EGFR responsive to erlotinib

@en

Getting out of a wheelchair: a ...... f EGFR responsive to erlotinib

@nl

prefLabel

Getting out of a wheelchair: a ...... f EGFR responsive to erlotinib

@ast

Getting out of a wheelchair: a ...... f EGFR responsive to erlotinib

@en

Getting out of a wheelchair: a ...... f EGFR responsive to erlotinib

@nl

P1433

Q34269139-4265B632-BC1E-4220-99BA-43FA01A31BDA

P1476

Q34269139-ECB4BC01-75C3-46D4-92D5-E43557A10ECC

P2093

Q34269139-0D5F07C3-F121-4B4E-A609-D3FA834D72C6

Q34269139-58F31439-61B5-4081-B069-237B43C531AE

Q34269139-68C5E15D-5E5D-485A-90FC-8C1CFC5C2A7C

Q34269139-6A6C43CD-8ABD-4158-8A90-382356BD56A6

Q34269139-713BBD6B-9737-4B5D-838B-9F641BD53922

Q34269139-7952C73C-AB4A-4925-8AFB-C19037FCC636

Q34269139-95A84C7F-178F-4A1E-A880-561C7650ED5B

Q34269139-98A5D367-14EB-46E2-B985-A3E17A65BEA8

P2860

Q34269139-099CD04A-6080-4C0E-AED7-CC28B47AA440

Q34269139-1694DBF3-124E-455C-8F65-2A2FB74C7185

Q34269139-51808ADD-DD83-4BF0-BE6C-52908DA02643

Q34269139-60B2AFF9-A7B6-4071-B631-4453D31C09C8

Q34269139-999C9C24-A2BE-4A2C-9B37-6DE94B3D668E

Q34269139-DEB2DD77-E0A7-47BD-8D54-5814FDF939ED

Q34269139-DF2F09C1-ECD8-4AC3-9FAE-4A8AE388B138

Q34269139-E69130BF-11AE-4B17-B9E8-C3C8F79D1C60

Q34269139-E782786C-CEF7-4EE5-86DD-79261738D25D

Q34269139-E988FCF0-E33A-479A-95D1-64BD345A732A

P2888

Q34269139-E0019544-6053-46A5-A0B7-6BA8BF319583

P304

Q34269139-18D35355-3F80-4E2A-AAC1-4E2337DA7DE6

P31

Q34269139-E9596B62-B29F-40F7-94F4-FEC53931F11A

P356

Q34269139-1277B4E3-A8FB-4BAC-98CE-18C50946C40F

P478

Q34269139-95C109BC-1BBC-4DB3-891D-B835A89DE2A4

P50

Q34269139-9D68AA12-9AAD-4AEC-9410-C188A2D5829D

P577

Q34269139-2D4A0E17-A515-45D0-8D6C-23F7357F7A5B

P5875

Q34269139-93C9C28E-80A0-4C34-B3F7-0C25F7C29499

P6179

Q34269139-6D5CC40B-9850-442C-B5F5-9418B7D091DE

P698

Q34269139-A4EE6323-85C1-4B56-B2A7-E021F7DD592C

P921

Q34269139-F7C7A588-50E2-47C3-B76F-B9FE6327D0D3

P932

Q34269139-8A9035E2-2079-428D-AF33-8838BC71CB1C

P356

2193-1801-3-507

P1433

P1476

Getting out of a wheelchair: a ...... f EGFR responsive to erlotinib

@en

P2093

Abed Agbarya

http://www.w3.org/2001/XMLSchema#string

Flavio Lejbkowicz

http://www.w3.org/2001/XMLSchema#string

Haitam Nasrallah

http://www.w3.org/2001/XMLSchema#string

Ilana Goldberg-Cohen

http://www.w3.org/2001/XMLSchema#string

Jair Bar

http://www.w3.org/2001/XMLSchema#string

Meira Melamed-Frank

http://www.w3.org/2001/XMLSchema#string

Mira Wollner

http://www.w3.org/2001/XMLSchema#string

Orit Kaidar-Person

http://www.w3.org/2001/XMLSchema#string

P2860

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.

Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib.

EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma

Molecular modeling and description of a newly characterized activating mutation of the EGFR gene in non-small cell lung cancer.

Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond.

Frequency and type of epidermal growth factor receptor mutations in moroccan patients with lung adenocarcinoma.

Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.

An uncommon insertion mutation in exon 19 of EGFR showed stable disease after TKI treatment.

P2888

2193-1801-3-507

P304

507

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/2193-1801-3-507

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-09-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266625580

http://www.w3.org/2001/XMLSchema#string

P6179

1039665755

http://www.w3.org/2001/XMLSchema#string

P698

25279299

http://www.w3.org/2001/XMLSchema#string

P921

P932

4180504

http://www.w3.org/2001/XMLSchema#string